Evidence map›Paper›PMID 36425201›Full record

ArticleRSC advances2022

Quantification of clofarabine in urine and plasma by LC-MS/MS: suitable for PK study and TDM in pediatric patients with relapsed or refractory ALL.

Xi Zhang, Xinbei Jia, Weihang Tong, Hui Chen, Ning Lei, Guangrun Li, Jun Tai, Pengfei Li

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Xi ZhangPharmacy Department of Beijing Chaoyang Hospital, Capital Medical University No. 8 Gongti South Road, Chaoyang District Beijing China lee-pf@163.com.
Xinbei JiaDepartment of Otorhinolaryngology, Children's Hospital, Capital Institute of Pediatrics No. 2 Yabao Road, Chaoyang District Beijing China trenttj@163.com.
Weihang TongPharmacy Department of PLA Rocket Force Characteristic Medical Center No. 16 Xinwai Street Xicheng District Beijing China.
Hui ChenPharmacy Department of Beijing Chaoyang Hospital, Capital Medical University No. 8 Gongti South Road, Chaoyang District Beijing China lee-pf@163.com.
Ning LeiPharmacy Department of PLA Rocket Force Characteristic Medical Center No. 16 Xinwai Street Xicheng District Beijing China.
Guangrun LiPharmacy Department of Beijing Chaoyang Hospital, Capital Medical University No. 8 Gongti South Road, Chaoyang District Beijing China lee-pf@163.com.
Jun TaiDepartment of Otorhinolaryngology, Children's Hospital, Capital Institute of Pediatrics No. 2 Yabao Road, Chaoyang District Beijing China trenttj@163.com.
Pengfei LiPharmacy Department of Beijing Chaoyang Hospital, Capital Medical University No. 8 Gongti South Road, Chaoyang District Beijing China lee-pf@163.com.ORCID https://orcid.org/0000-0002-4756-5549
Capital Medical University · CNChildren's Hospital of Capital Institute of Pediatrics · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clofarabine is approved for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years. Its pharmacokinetic (PK) exposure is strongly related to clinical outcomes and high risk of adverse reactions. PK-guided dosing of nucleoside analogs has the potential to improve survival and reduce toxicity in children. Considering that blood collection is an invasive operation and that the volume of blood collected is usually limited in pediatric ALL patients, a convenient and efficient method for the quantification of clofarabine in human urine and plasma was established with an LC-MS/MS system. Standard curves were shown to be liner in the range of 2.00-1000.00 ng mL

Identifiers

PMID36425201
PMCPMC9672991
OpenAlexW4310334462

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.